文献速递骨软组织肉瘤与黑色素瘤

免疫代谢抗肿瘤药物靶点发现鉴定出雌激素相关受体α

Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha.
PubMed 文献 · Cancer Discov · 2023-01-01

研究开发了多组学计算工具BipotentR,用于寻找同时调控肿瘤免疫和另一致癌通路的癌细胞特异性调节因子,鉴定出38个候选免疫代谢调节因子;这些因子的肿瘤活性可通过机器学习和深度神经网络对抗PD-1治疗黑色素瘤患者进行应答分层,并发现ESRRA在免疫治疗耐药肿瘤中激活,其抑制通过抑制能量代谢和激活两种免疫机制杀伤肿瘤。

要点

  • BipotentR多组学方法鉴定出38个候选免疫代谢调节因子。
  • 这些调节因子的肿瘤活性可对抗PD-1治疗的黑色素瘤患者进行应答分层。
  • ESRRA在免疫治疗耐药肿瘤中激活,其抑制通过抑制能量代谢和激活两种免疫机制杀伤肿瘤。

核心结论

  • BipotentR提供评估患者应答和发现同时通过多种机制杀伤肿瘤的药物靶点的资源;抑制最靠前的候选靶点ESRRA通过抑制能量代谢和对两种免疫机制的影响杀伤肿瘤。

研究设计与样本

  • 研究首先开发了计算机多组学方法BipotentR,用于寻找同时调节肿瘤免疫和另一致癌通路的癌细胞特异性调节因子,并鉴定出38个候选免疫代谢调节因子;随后使用机器学习和深度神经网络方法分析这些调节因子的肿瘤活性,对黑色素瘤患者抗PD-1治疗的应答进行分层;还通过应用于血管生成和生长抑制因子逃逸通路展示了BipotentR的广泛用途。

主要发现

  • 这些调节因子的肿瘤活性通过机器学习和深度神经网络方法对抗PD-1治疗的黑色素瘤患者进行应答分层,提高了当前生物标志物的预测能力。
  • 最靠前鉴定的调节因子ESRRA在免疫治疗耐药肿瘤中激活。
  • 抑制ESRRA通过抑制能量代谢和激活两种免疫机制杀伤肿瘤:细胞因子诱导导致促炎巨噬细胞极化,以及抗原呈递刺激将CD8+ T细胞招募到肿瘤中。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Drugs that kill tumors through multiple mechanisms have the potential for broad clinical benefits. Here, we first developed an in silico multiomics approach (BipotentR) to find cancer cell-specific regulators that simultaneously modulate tumor immunity and another oncogenic pathway and then used it to identify 38 candidate immune-metabolic regulators. We show the tumor activities of these regulators stratify patients with melanoma by their response to anti-PD-1 using machine learning and deep neural approaches, which improve the predictive power of current biomarkers. The topmost identified regulator, ESRRA, is activated in immunotherapy-resistant tumors. Its inhibition killed tumors by suppressing energy metabolism and activating two immune mechanisms: (i) cytokine induction, causing proinflammatory macrophage polarization, and (ii) antigen-presentation stimulation, recruiting CD8+ T cells into tumors. We also demonstrate a wide utility of BipotentR by applying it to angiogenesis and growth suppressor evasion pathways. BipotentR (http://bipotentr.dfci.harvard.edu/) provides a resource for evaluating patient response and discovering drug targets that act simultaneously through multiple mechanisms. SIGNIFICANCE: BipotentR presents resources for evaluating patient response and identifying targets for drugs that can kill tumors through multiple mechanisms concurrently. Inhibition of the topmost candidate target killed tumors by suppressing energy metabolism and effects on two immune mechanisms. This article is highlighted in the In This Issue feature, p. 517.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Sahu A, Wang X, Munson P, et al. Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha. Cancer Discov. 2023. PMID: 36745048. doi:10.1158/2159-8290.CD-22-0244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。